Aspirin – Friend or Foe After Breast Cancer?

Some studies suggest aspirin users may have lower breast cancer risk . But how does aspirin affect those who have received treatment for breast cancer?

What Is Aspirin?

Aspirin, found in many medicine cabinets, is a non-steroidal anti-inflammatory drug (NSAID). Chemist Dr. Felix Hoffmann, on 10 August 1897 , synthesized salicylic and acetic acids to produce pure acetylsalicylic acid. Derived from willow bark and commercially called aspirin, its practical benefits and relatively low adverse-effect risk made it indispensable. It commonly reduces fever, pain, and inflammation. Long-term low doses also thin blood in arrhythmia, heart failure, diabetes, and vascular obstruction, preventing or reducing related cardiovascular diseases . It inhibits cyclooxygenase (COX). COX1 synthesizes clotting-related thromboxane A2; COX2 synthesizes prostaglandins involved in fever, pain, and inflammation perception. Inhibiting COX1 thins blood; inhibiting COX2 reduces these sensations. Aspirin does not treat their cause, only perception. Underlying causes must be diagnosed and treated.

Study Details

Regarding aspirin, some recent studiessuggested breast cancer risk reduction up to 20 percent. However, new University of North Carolina (UNC) research states how aspirin use after breast cancer affects outcomes remains unclear . UNC researchers write in Cancer that “underlying biological mechanisms and epidemiological findings on aspirin use, breast cancer prognosis, and mortality are limited and inconsistent.” While aspirin may protect some survivors' health, others show no benefit. Who benefits and how? The UNC team investigated. Epigenetic Changes (DNA Interaction) May Be Key Recent studies concluded: “Chronic inflammationis central to developing many cancers, including breast cancer; aspirin may reduce risk through anti-inflammatory properties.” This study examined human DNA more closely, asking whether prediagnosis aspirin interacts in 13 breast-cancer-related genes with DNA methylation (epigenetic changes) and affects treatment outcomes. Methylation switches DNA molecules on or off through chemical reactions to external factors. It does not change the gene but may change its activity and potentially cause health problems including cancer.

• Related topic: Genes Need Education Too! Epigenetic Cancer Treatments The 13 genes studied were APC, BRCA1, CDH1, CYCLIND2, DAPK1, ESR1, GSTP1, HIN, CDKN2A, PR, RAR beta, RASSF1A, and TWIST1. Data came from 1.266 women with breast cancer. Among women taking aspirin at least weekly up to 6 weeks before diagnosis and showing BRCA1 methylation, a gene mutation capable of driving breast cancer, researchers found %67 higher post-treatment all-cause mortality. Conversely, women using aspirin before diagnosis with BRCA1 and PR methylation not detected had cancer mortality reduced by % 22-40.

Conclusion

Research suggests medications influence gene activity through epigenetic mechanisms. Aspirin triggers epigenetic changes differing between individuals. High-risk women should therefore not start or stop aspirin outside their prescribed regimen. Its effects after breast cancer remain unclear, precluding firm recommendations. Advancing genetic analyses and larger population studies will deepen understanding of mapping and gene interactions. *

Common Cancer Epigenetic Mechanisms Are “DNA Methylation” and “Histone Modifications”

They do not alter gene structure but determine activity

1. DNA Methylation: Chemical methyl groups are added to DNA. The modified gene region remains inactive and cannot perform its function.

2. Histone Modifications: These determine gene activity. DNA is threadlike within cells; histone proteins wrap it into a tight structure. Genes inside cannot be read and remain inactive.

Research finds the most frequent cancer mutations occur in DNA methylation mechanisms, though excess or deficiency depends on gene type.